Prior studies have demonstrated that amino acid substitutions at the B22 position can lead to a spectrum of diabetes phenotypes, ranging from mild forms of Maturity-Onset Diabetes of the Young (MODY) to severe insulin-deficient neonatal diabetes [5,6,7]. This evidence concerns the gene INS and diabetes mellitus.